ISSUE 1406
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The use of intracoronary stents in angioplasty procedures has improved both short- and long-term success rates. In recent years, drug-eluting stents (DESs) have largely replaced bare-metal stents (BMSs).1
BARE-METAL STENTS — Intracoronary stents are safer and more effective than balloon angioplasty for most percutaneous coronary interventions. They have markedly reduced the incidence of periprocedural complications, but are associated with high rates (20-25%) of restenosis. Restenosis is a biological response of the vessel to mechanical injury. Local barotrauma to the vessel from balloons or stents results in neointimal proliferation within the stents that narrows the lumen. Restenosis usually occurs during the first 6-9 months after a balloon angioplasty or insertion of a BMS. The risk of in-stent restenosis is increased in patients with diabetes, small-diameter vessels, long
... more1. S Bangalore et al. Short- and long-term outcomes with drugeluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125:2873.
2. Drug-eluting stents. Med Lett Drugs Ther 2003; 45:23.
4. Antiplatelet therapy for patients with stents. Med Lett Drugs Ther 2008; 50:61.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1406b
Electronic, downloadable article - $45
